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Atrial Fibrillation Ablation
in the Real World*
David E. Haines, MD
Royal Oak, Michigan
Atrial fibrillation (AF) ablation has offered the promise to
free patients of symptoms of palpitations, dyspnea, and
fatigue, as well as eliminate the need for use of chronic drug
therapy with agents that sometimes have significant risks,
cost, and inconvenience for the patient. The belief among
many is that elimination of symptomatic AF with ablative
procedures will also restore patients to the AF-free natural
history curve, with reduction in stroke and mortality long
term. These advantages are compelling, and they explain the
wide adoption of a procedure that is technically challenging
and has results that can be characterized as mediocre at best.
Despite the fact that reports have claimed procedural
success rates of 76% to 91% (1–4), carefully monitored
clinical trials performed by experienced operators have
indicated a true success rate in the range of 66% (5). In
addition, procedural complication rates that are widely
quoted to patients when decisions about risk versus benefit
of AF ablation are being weighed are derived from publi-
cations that depend primarily upon self-reporting by single
research centers or by centers participating in surveys (6,7).
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These reports most certainly underestimate the true preva-
lence of adverse events related to this intervention. It is
therefore imperative that alternate methodologies are pur-
sued to independently corroborate rates of arrhythmia
recurrence and complications with AF ablation in the real
world.
In this issue of the Journal, Shah et al. (8) presented data
rom the Healthcare Utilization Project California State
npatient Database tracking prevalence of AF ablation
rocedures, acute procedure-related complications, and sub-
equent cause-specific readmissions for recurrent arrhyth-
ias or procedural complications. This important study
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real world. With this methodology, more than 4,000 pa-
tients who underwent an initial AF ablation procedure
during a 4-year period were identified. The population
seemed typical for patients who undergo this procedure
nationally in that they were somewhat younger and had
fewer comorbidities than the typical AF patient (9,10). The
researchers found that complications occurred in 5% of
patients and that one-half of those complications were
vascular in nature. A total of 2.5% of patients had perfora-
tion or tamponade, a higher incidence than the 1.3% rate
reported in the worldwide survey on AF ablation (6). The
incidence of stroke and death were 0.24% and 0.02%,
respectively, and were similar to published reports. The
mean length of stay for patients with procedures reported as
uncomplicated was 1.46 days, with hospitalization 3 days
in 8.6% of these patients, implying that the complication
rate might have been underreported. Not surprisingly,
increasing age, female sex, and the comorbidities heart
failure, hypertension, chronic renal disease, and lung disease
were associated with procedural complications (11–14). In
the multivariable analysis, the comorbidities did not reach
significance, most likely because their prevalence tracked
with age.
The other main independent predictor of procedural
complications in the study of Shah et al. (8) was lack of
procedural experience as indicated by volume of procedures
performed at each center. It was striking that the mean
volume of AF ablations per hospital was 15.4 per year
overall. Because high-volume centers were included in the
analysis, the median number of AF ablations per hospital
annually (not provided) was certainly much lower. The
researchers did not have data regarding the number of
operators, but it is likely that the total number of operators
was greater than the number of hospitals, which would
result in a lower median number of procedures per operator
annually. Thus, it would appear that one of the most
technically challenging procedures in the field of interven-
tional cardiac electrophysiology is commonly being per-
formed by physicians lacking appropriate experience.
What is unknown and unknowable from the present
study using their methodology is the overall recurrence rate
of AF after ablation. Shah et al. (8) reported that the 1- and
2-year rates of freedom from hospital admission in Califor-
nia for recurrent AF were 78.3% and 70.4%, respectively.
However, most patients who experience AF recurrence are
managed entirely in the outpatient setting. The majority of
rehospitalizations reported were readmissions for repeat
catheter ablation. So, was the true rate of freedom from
arrhythmia recurrence at 1 year 70%, or 50% or 30%? This
cannot be determined. The rehospitalization rates are inter-
esting data in that they emphasize the ongoing health
resource utilization by these patients after attempted cath-
eter ablation, but they should by no means be considered as
surrogate data for actual arrhythmia recurrence rates.
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pulmonary vein isolation, pulmonary vein reconnection rates
are high (15–18). It is often necessary to perform additional
ablation at a follow-up procedure to achieve permanent vein
isolation and procedure success. Most high-volume AF ablation
centers report a repeat procedure rate of 27% to 51%
(6,19–21), but only 17.4% of patients from the present
study had a second procedure during the study period in
California. It is possible that some patients traveled out of
state for repeat procedures, but it is more likely that
low-volume operators lacked the experience or confidence
to go forward with additional ablation.
The present study raises many familiar concerns for the
field of catheter ablation of AF. First, the real-world success
rate of this procedure is unknown but is likely considerably
lower than published reports from single-center studies.
Second, complication rates are significant, as are late hos-
pitalization rates. Data from many investigations in AF
ablation as well as different disciplines within cardiovascular
medicine have repeatedly demonstrated that operator and
hospital procedure volume are inversely correlated with poor
outcomes (12,14,22,23). Once again, the correlation be-
tween experience and procedural results was demonstrated
in the study of Shah et al. (8). It is problematic that complex
procedures continue to be performed at very low-volume
centers in the U.S. medical system. As long as a hospital is
able to profit from supporting interventional procedures by
its physicians, there will be a tendency to set a low bar for
granting privileges to any doctor who claims proficiency.
Although no honest healthcare provider would ever con-
sciously place a patient needlessly in harm’s way, there are
strong forces (economic, reputational, convenience) that
prevent subspecialists from referring patients to other sub-
specialists within the same field. Concentration of expen-
sive, highly technical procedures such as coronary artery
bypass grafting in high-volume referral centers has been
achieved in part with the certificate of need process (24,25)
However, this course of action is cumbersome, politically
charged, and unpopular in many circles. Professional soci-
eties can establish standards for training and minimal
procedure volumes necessary for competency. The Heart
Rhythm Society, in conjunction with other professional
organizations from the United States and Europe, has
developed an expert consensus statement on catheter and
surgical ablation of AF (8), with the updated document
scheduled for release in January 2012. Unfortunately, con-
forming to these standards is voluntary, and standards based
upon procedural volume are usually arbitrary and controver-
sial (26). Ultimately, the torte system is the back stop to
prevent operators from working beyond the limits of their
experience and training, but that punitive process is expen-
sive and inefficient, and just addresses the most egregious
cases of abuse and only after substantial harm has come to
the patient.
It is imperative that any center that commits to estab-
lishing an AF ablation program initiates robust qualityassurance methodology that tracks the long-term outcomes
after intervention. Until this is done, it is impossible to
understand whether the individual operators and the hos-
pital team are providing acceptable service to their patients.
When patients are counseled about the risks and benefits of
AF ablation, real data reflecting the operator’s and team’s
results should be quoted, not data from an unaffiliated
high-volume center from a different continent. If healthcare
providers do not regulate themselves, it is inevitable that
outside bodies will impose regulation upon us.
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